- Home
- CPRX vs CGAU Comparison
CPRX vs CGAU Comparison
Compare CPRX & CGAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRX | CGAU |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CPRX | CGAU |
|---|---|---|
| Price | $31.28 | $17.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $35.00 | $16.67 |
| AVG Volume (30 Days) | ★ 2.9M | 1.3M |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.16% |
| EPS Growth | ★ 28.24 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $119,072,803.00 | N/A |
| Revenue This Year | $9.20 | $25.17 |
| Revenue Next Year | $10.51 | $13.62 |
| P/E Ratio | $62.58 | ★ $11.74 |
| Revenue Growth | ★ 16.39 | N/A |
| 52 Week Low | $19.05 | $6.71 |
| 52 Week High | $32.56 | $21.17 |
Technical Indicators
Market Signals| Indicator | CPRX | CGAU |
|---|---|---|
| Relative Strength Index (RSI) | 72.86 | 50.23 |
| Support Level | $31.00 | $17.51 |
| Resistance Level | $31.33 | $19.95 |
| Average True Range (ATR) | 0.08 | 0.72 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 81.94 | 48.37 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
About CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.